Skip to content
Screener

TG Therapeutics TGTX Q2 2025 earnings

Reported August 4, 2025 · Before market open

Revenue$141.1MMiss by $5.1M
EPS$0.17Miss by $0.15
Revenue estimate$146.3M
EPS estimate$0.32

Next report

Nov 2, 2026 (in a month)
Revenue estimate$245.2M
EPS estimate$0.36

Financials

Q2 2025

Income statement

See full
Revenue$141.1M+92.1%
Gross profit$122.2M+87.5%
Operating income$34.8M+295%
Net income$28.2M+310%
EPS (diluted)$0.17+325%

Balance sheet

See full
Cash & equivalents$129.1M+55.7%
Total debt$253.7M+125%
Total equity$276.4M+55.7%
Total assets$702.6M+75.1%

Cash flow

See full
CapEx$42.0K—

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$5.92B+115%
Enterprise value$6.05B+118%
P/E97.9×—
P/S13×+5.1×

Profitability

See full
Gross margin87%-5.8pp
Operating margin18.9%—
Net margin13.3%—

Returns & leverage

See full
Return on equity26.6%—
Debt / equity0.9×+0.3×
Current ratio3.9×+0.3×

FAQ

When did TG Therapeutics report Q2 2025 earnings?
TG Therapeutics (TGTX) reported Q2 2025 earnings on August 4, 2025 before market open.
What were TG Therapeutics's Q2 2025 revenue and EPS?
TG Therapeutics reported revenue of $141.1M and eps of $0.17 for Q2 2025.
Did TG Therapeutics beat estimates in Q2 2025?
Revenue missed the consensus estimate of $146.3M by $5.1M. EPS missed the consensus estimate of $0.32 by $0.15.
How did TG Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 92.1% from $73.5M a year earlier and eps grew 325.0% from $0.04.
Where can I find TG Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001437749-25-024480) and the 10-Q periodic report (0001437749-25-025745) directly on SEC EDGAR. The filing index links above go to sec.gov.